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ABSTRACT
Introduction Lifestyle modification is the mainstay of 
gestational diabetes mellitus (GDM) prevention. However, 
clinical trials evaluating the safety and efficacy of diet or 
physical activity (PA) in low- income and middle- income 
settings such as Africa and India are lacking. This trial 
aims to evaluate the efficacy of yoghurt consumption and 
increased PA (daily walking) in reducing GDM incidence in 
high- risk pregnant women.
Methods and analysis The study is a 2×2 factorial, 
open- labelled, multicentre randomised controlled trial 
to be conducted in Vellore, South India and The Gambia, 
West Africa. ‘High- risk’ pregnant women (n=1856) aged 
≥18 years and ≤16 weeks of gestational age, with at least 
one risk factor for developing GDM, will be randomised to 
either (1) yoghurt (2) PA (3) yoghurt +PA or (4) standard 
antenatal care. Participants will be followed until 32 
weeks of gestation with total active intervention lasting 
for a minimum of 16 weeks. The primary endpoint is GDM 
incidence at 26–28 weeks diagnosed using International 
Association of the Diabetes and Pregnancy Study Groups 
criteria or elevated fasting glucose (≥5.1 mmol/L) at 32 
weeks. Secondary endpoints include absolute values 
of fasting plasma glucose concentration at 32 weeks 
gestation, maternal blood pressure, gestational weight 
gain, intrapartum and neonatal outcomes. Analysis will 
be both by intention to treat and per- protocol. Continuous 
outcome measurements will be analysed using multiple 
linear regression and binary variables by logistic 
regression.
Ethics and dissemination The study is approved by 
Oxford Tropical Research Ethics Committee (44–18), ethics 
committees of the Christian Medical College, Vellore (IRB 
11367) and MRCG Scientific Coordinating Committee 
(SCC 1645) and The Gambia Government/MRCG joint 
ethics committee (L2020.E15). Findings of the study will 
be published in peer- reviewed scientific journals and 
presented in conferences.
Trial registration number ISRCTN18467720.
BACKGROUND
Gestational diabetes mellitus (GDM) accounts 
for 86% of hyperglycaemia during the preg-
nancy1 and is associated with significant intra-
partum complications, perinatal morbidity 
and long- term risk of developing type 2 
diabetes (T2D) and cardiovascular disease in 
both the mother and the offspring.2–4 Conse-
quent to the global rise in obesity prevalence 
and the introduction of more stringent diag-
nostic criteria by the International Association 
Strengths and limitations of this study
 ► This study will be the largest lifestyle intervention 
trial among high- risk gestational diabetes mellitus 
(GDM) mothers in India and Africa to evaluate the 
efficacy of daily yoghurt consumption and physical 
activity in reducing GDM incidence.
 ► The factorial design allows to evaluate the effec-
tiveness of independent and combined effects of 
yoghurt and physical activity on GDM incidence as 
well as test for interactions simultaneously.
 ► The inclusion of participants from two different low- 
income and middle- income settings with diverse 
cultural background, socioeconomic status, varied 
life- style behaviour and access to healthcare, will 
provide robust evidence of generalisability of these 
results across countries.
 ► Due to the nature of interventions, it is not possible 
to blind the study participants or research investiga-
tors, which may introduce bias and increase the risk 
of confounding.
 ► The selective screening and intervention in high- risk 
women using low- cost interventions is suitable for 
GDM prevention in low- resource settings such as 
India and Africa.
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of the Diabetes and Pregnancy Study Groups (IADPSG), 
the global prevalence of GDM has been estimated at 
17.8% (range 9.3%–25.5%).5 In low- income and middle- 
income countries (LMICs), especially in India and Africa, 
there are few nationwide estimates of GDM burden. 
Cross- sectional studies using variable diagnostic criteria 
report GDM prevalence ranging between 10%–16% in 
India6 7 and 11%–14% in Africa,8 9 which is higher than 
the reported prevalence from high- income countries like 
the UK (2%–3% using National Institute for Health and 
Care Excellence guidelines) and USA (2%–10% using 
various criteria including IADPSG).10 11 Direct compar-
isons of these estimates may not be appropriate due to 
inconsistency in diagnostic criteria. Nevertheless, it seems 
clear that LMICs are facing a high burden of GDM.
In normal pregnancy, the physiological response to 
reduced insulin- mediated glucose removal is an increase 
in insulin secretion to maintain normoglycaemia.12 In 
GDM, insufficient β-cell plasticity leads to an inability to 
secrete adequate quantities of insulin to counterbalance 
the insulin resistance (IR), and this process is accelerated 
in obesity. Women with chronic IR states such as prepreg-
nancy excess body weight or obesity, impaired glucose 
tolerance prior to pregnancy, polycystic ovarian syndrome 
(PCOS), previous GDM, advanced maternal age and rapid 
gestational weight gain (GWG), have a higher risk for 
developing glucose intolerance during pregnancy.13 The 
hyperglycaemia of GDM rapidly abates following delivery 
and normoglycaemia usually returns within 12 weeks. 
However, 50%–70% of GDM mothers progress to T2D 
within 5–10 years postpartum14 suggesting that GDM may 
be a prodrome of ‘common T2D’ and may reflect the 
underlying T2D frequency in the community.15
Screening for GDM
Following the demonstration of a linear relationship 
between maternal glycaemia and obstetric and perinatal 
outcomes by the Hyperglycaemic and Adverse Pregnancy 
Outcome study,16 17 the IADPSG recommends universal 
screening of all women at first antenatal visit, without 
restriction to high- risk pregnant women, in order to iden-
tify all potential GDM cases.18 However, some countries 
have adopted selective screening, despite the possibility 
of missing over 40% of GDM cases.19 In low- economic 
setting like the LMICs, this approach may be more cost- 
effective and oral glucose tolerance test (OGTT) may be 
less beneficial to low risk women.20
GDM management
The main goal of lifestyle modification using diet and 
physical activity (PA) in pregnancy is to prevent excessive 
GWG, improve maternofetal outcomes and prevent the 
onset/subsequent progression to GDM/T2D in both the 
mother and the new born.21 In order to maximise the 
benefit of such interventions, the best strategy is likely to 
target high- risk populations by initiating early interven-
tions during the ‘critical window’, that is, before insuffi-
cient β-cell plasticity sets in22 (figure 1).
Dietary interventions in pregnancy
Meta- analysis of dietary intervention trials in pregnant 
women has shown that diet modification in any form 
resulted in a 61% risk reduction in GDM incidence (rela-
tive risk (RR) 0.39, 95% CI 0.23 to 0.69).23–26 Besides 
macronutrient modification, dairy products, particu-
larly yoghurt has been shown to lower the risk of T2D,27 
through mechanisms such as reduction in inflammatory 
signalling and gut permeability giving rise to a range of 
putative signals from the gut to the systemic circulation 
which ameliorate metabolic endotoxaemia.28–30 Differ-
ences in gut microbial composition between healthy 
pregnant and GDM women provide evidence of a poten-
tial role of altered gut microbiota in pregnancy- related 
metabolic dysfunction.31 32
Figure 1 Relationship between pancreatic beta cell plasticity with advancement in gestational age.
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Although exact mechanisms of the positive effects 
of the manipulating the gut microbiome during preg-
nancy is not studied, evidence from epidemiological data 
suggest that using fermented dairy products or probi-
otics prior to and during the pregnancy has positive 
impact on maternal weight, blood pressure (BP), IR and 
plasma lipid profile.31 33–37 The ‘Probiotics and Pregnancy 
Outcome’ study showed that incident GDM was lower 
in women supplemented with probiotics compared with 
diet/placebo or control groups (16% vs 36% vs 34%).38 
The Nutrition, Allergy, Mucosal immunology and Intes-
tinal microbiota study showed reductions in glucose 
and insulin concentration, GDM incidence and central 
adiposity, possibly mediated by anti- inflammatory cyto-
kine production in probiotic supplemented pregnant 
women.39 40 Multiple pieces of evidence also support a 
positive relationship between probiotic yoghurt supple-
mentation during pregnancy and improved glycaemic 
profile in women with GDM or obesity.41–43
Physical activity in pregnancy
PA directly impacts non- insulin mediated glucose utilisa-
tion through translocation of glucose transporter type 4 
on skeletal muscle.44 45 PA during the pregnancy is safe 
and American College of Obstetrics and Gynaecology 
(ACOG) guidelines recommend ≥30 min of moderate PA 
performed at an intensity of 3–6 metabolic equivalents, 
which corresponds to brisk walking at 5–7 km/hour on 
most days of the week.46
Evidence of a beneficial effect from PA- intervention 
during the pregnancy mostly come from high- income 
countries and include a wide range of exercise programme 
that vary in their intensity, duration, frequency and assess-
ment techniques. Results show that regular PA in any 
form improves maternal (hyperglycaemia, hypertension, 
weight gain and cardiovascular function),47 obstetric 
(pre- eclampsia, shoulder dystocia, preterm births) 
and neonatal outcomes (low birthweight or small- for- 
gestational age (GA), decreased fat mass, improved stress 
tolerance and advanced neurobehavioural maturation).48
Meta- analysis of randomised controlled trials (RCTs) of 
PA intervention (eight studies, n=1441) in obese/over-
weight women has shown a 24% reduction in GDM inci-
dence in the intervention groups (RR 0.76, 95% CI 0.56 
to 1.03; p=0.07) with moderate heterogeneity between 
studies (I2=50%, p=0.05).49 Some studies have shown 
negative or neutral effects, including a Cochrane review 
(five studies, n=1115) of PA on GDM incidence,50–52 and 
this is likely to be related to study heterogeneity, bias, type 
of exercise, timing, duration and intensity of exercise and 
also subjective assessments. Nevertheless, the potential 
beneficial effects of effective PA intervention in preg-
nancy should not be underestimated.
The knowledge gap on effectiveness of PA interventions 
in LMIC settings is particularly challenging in women 
from Asian Indian and African backgrounds where the 
baseline PA level is generally considered low. The ability 
to engage pregnant women from diverse ethnic groups 
will also be determined by population- specific socioeco-
nomic and cultural factors.
Combined approaches in pregnancy
Targeting multiple risk factors simultaneously may have a 
synergistic effect to reduce GDM. Combined approaches 
have shown favourable improvements in maternal and 
fetal outcomes, particularly GWG, which is a potentially 
modifiable risk factor for GDM development.53–57 Two 
RCTs using combined interventions in high- risk women 
(body mass index (BMI) ≥30 kg/m2), the UPBEAT 
(UK Pregnancies Better Eating and Activity Trial)58 
and RADIEL trial (Gestational diabetes mellitus can be 
prevented by lifestyle intervention: the Finnish gestational 
diabetes prevention study),59 showed 0.55 kg and 0.58 kg 
reduction in GWG, respectively. The RADIEL trial addi-
tionally showed about 36% reduction in GDM incidence 
(crude RR 0.64; 95% CI 0.38 to 1.09) in the intervention 
group. A recent Cochrane review of combined interven-
tions showed a tendency towards reduced GDM risk (RR 
0.85, 95% CI 0.71 to 1.01; 6633 women, 19 RCTs) and 
reduced weight gain (mean difference −0.89 kg, 95% CI 
−1.39 to −0.40; 5052 women, 16 RCTs).60
HYPOTHESIS
We hypothesise that daily yoghurt consumption and/or 
increased PA will reduce the risk of developing GDM in 
‘high- risk’ pregnant women.
AIMS
To examine if daily yoghurt consumption and/or PA 
beginning from ≤16 weeks of gestation in ‘high- risk’ preg-




To establish the efficacy and safety of low- cost interven-
tions (fermented yoghurt consumption/daily walking/
both) to prevent GDM in two LMIC settings.
Secondary objectives
1. To evaluate the effect of yoghurt/daily walking/com-
bination of both on fasting glucose concentration at 
32 weeks of gestation, GWG, BP, intrapartum and neo-
natal outcomes.
2. To identify barriers that prevent participation/adher-
ence to lifestyle changes during pregnancy and thus 
design culturally and socially acceptable, cost- effective 
interventions that can be implemented successfully in 
LMICs.
CENTRES
Christian Medical College, Vellore, India.
MRC unit at LSHTM, Fajara, The Gambia.
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DESIGN
The study is a 2×2 factorial design and eligible women will 
be randomised to either one of the arms—(1) yoghurt 
(2) PA (3) yoghurt+PA and (4) standard care.
ELIGIBILITY CRITERIA
The study will include pregnant women aged ≥18 years 
and GA ≤16 weeks and meeting at least one risk- factor 
for GDM (booking BMI ≥25 kg/m2, age ≥25 years; a 
first- degree relative with diabetes; a previous pregnancy 
complicated by GDM, pre- eclampsia/eclampsia and/or a 
large baby (≥3.5 kg); a history of PCOS/impaired fasting 
glucose) and not currently on any medication that is 
known to interfere with glucose metabolism.
Exclusion criteria
 ► GDM diagnosed prior to screening visit based on 
IADPSG criteria or documented raised glycosylated 
haemoglobin (HbA1c), that is, either fasting glucose 
≥5.1 mmol/L or 1 hour glucose≥10.0 mmol/L or 
2 hour glucose ≥8.5 mmol/L, or a documented HbA1c 
of ≥6.5% at first booking.
 ► History of pregestational diabetes, severe hyperemesis 
in the first trimester.
 ► History of recurrent (≥2) first trimester spontaneous 
abortions, stillbirth, significant antepartum or post-
partum haemorrhage in previous pregnancies.
 ► Multiple gestation in the current pregnancy.
 ► Uncontrolled pregestational or gestational hyperten-
sion (BP >150/100 mm Hg) on treatment.
 ► Previous child born with congenital anomalies.
 ► Pregnancy following in vitro fertilisation or any 
assisted reproductive technology.
 ► Previous or current psychiatric illness on medication, 
epileptic seizures or on antiepileptic medication,
 ► Women meeting absolute contraindications for PA 
during the pregnancy as recommended by the ACOG 
(heart disease, restrictive lung disease, incompetent 
cervix/cerclage, pregnancies at risk for premature 
labour, gestational hypertension, severe anaemia).
METHODS
Women attending obstetric outpatient clinics of the Chris-
tian Medical College, Vellore, India and MRC Unit in The 
Gambia operating in four centres in The Gambia (Brikama 
Major Health Centre, Bundung Maternal and Child 
Hospital, Barfrow Medical Centre and Edward Francis 
Small Teaching Hospital) will be informed about the study 
and assessed for eligibility. Following informed consent, 
women enrolled in the study will be asked to attend five 
scheduled visits (screening, run- in phase, randomisa-
tion, visits 1, 2 and 3) as shown in figure 2 and detailed 
in the protocol (online supplemental file 1). The study is 
expected to run from September 2018 to August 2021.
RANDOMISATION
Participants will be randomly allocated to one of the 
following arms (1) yoghurt (2) PA (3) yoghurt +PA or (4) 
standard care following an allocation schedule prestrat-
ified for centre, age and BMI. A variable block rando-
misation, stratified by centre and then by age, (<25 and 
≥25 years) and BMI (<25 and ≥25 kg/m2) will be gener-
ated, using a password- protected access database devel-
oped by an independent statistician not involved with trial 
participants. If a woman has more than one risk factor, 
she will be allocated to the strata depending on the first 
of the risk factors in the hierarchical block randomisation 
procedure (age or BMI). In India, the allocation will be 
performed using a computer interface (Access database), 
while separate computer- generated randomisation lists 
for each strata combination (age X BMI) will be prepared 
for each health facility in the Gambia. Due to logistic 
limitations, this will be implemented using pre- issued 
opaque, sealed envelopes containing the allocation code.
INTERVENTIONS
Dietary intervention
Yoghurt will be prepared locally at the dietary department 
in CMC, Vellore and at Kombo Dairy farm in The Gambia 
based on a common recipe and using the same starter 
culture containing Lactobacillus spp and Bifidobacterium spp at 
107 CFU. Yoghurt will be prepared in batches and an internal 
quality check will be performed to ensure that the bacterial 
species and colony count are maintained with each batch. 
Participants in the active yoghurt arm will consume 200 g/
day of regular, unflavoured, fermented yoghurt throughout 
the active intervention period independent of the timing of 
their regular meal. Yoghurt will be dispensed either daily or 
weekly as feasible by the study centre and possibility of storage 
in refrigerator at participants’ homes when not in use. 
Compliance with yoghurt will be assessed using pot count by 
field workers. All participants will receive dietary counselling, 
will not be advised to stop their regular dairy consumption, 
assuming that any effect on the outcome will be related to the 
trial yoghurt consumed. Information on background dairy 
consumption will be collected at each scheduled visit using a 
standardised DAIRY consumption questionnaire.
PA intervention
The PA activity intervention will include daily walking to 
increase the individual target step count, monitored using a 
wrist- mounted accelerometer device (Garmin Vivofit 4 fitness 
band).
The baseline step count will be recorded in all participants 
(blinding the step count on the device) for 7 days, with no 
emphasis on step count and/or activity during the run- in 
phase. At randomisation, baseline step count will be calcu-
lated as the average over 7 days including 2 weekend days. 
An individual target will be set, to a 40% or greater increase 
in daily step count compared with the baseline reading. 
The increment of 40% was based on a feasibility estima-
tion. Systematic reviews have shown that simple pedometer 
interventions can lead to a sustained increase of around 
2000–2500 steps a day in a great number of populations and 
settings.61 62 The background step count in these populations 
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was reasonably low (~5000), which will mean that 2000 addi-
tional step represent 40%.
The step count reading on the device will be unblinded 
after randomisation for women in the active PA arms, to 
provide visual feed back to the participants and to motivate 
them to achieve their daily target step count. Women in the 
non- PA arm will continue to use their fitness bands blinded 
throughout the study to measure their routine PA behaviour. 
Step count data will be periodically uploaded using Garmin 
application by the field worker to quantify compliance moni-
toring and counselling to participants in the PA arm. As the 
device is water resistant, the participants would be instructed 
to wear it day and night.
STUDY ASSESSMENT
Clinical measurements
Detailed study- related procedures, as outlined in table 1 
and routine antenatal examination will be carried out 
at all study visits. All measurements will be standardised 
between the two study centres and will be carried out as 
detailed in study- specific standard operating procedures 
(SOPs).
Laboratory tests
Study participants will undergo a 75 g OGTT at screening 
and visit 2 (week 26–28 GA) following an 8- hour overnight 
fast. Additional fasting plasma glucose will be measured at 
the end- of- study visit (week 32). Blood glucose measure-
ments will be analysed using a Roche Cobas 800 autoanal-
yser at respective laboratories (Department of Clinical 
Biochemistry in Vellore, India and the MRCG at LSHTM, 
The Gambia). Other routine antenatal laboratory tests, 
including haemoglobin will be done as a part of routine 
antenatal care according to local guidelines.
GDM ascertainment
IADPSG criteria will be used to diagnose GDM using an 
OGTT at weeks 26–28. GDM diagnosis will be established 
if either fasting glucose ≥5.1 mmol/L or 1- hour glucose 
≥10.0 mmol/L or 2- hour glucose ≥8.5 mmol/L.
Questionnaire-based assessments
Standardised questionnaires will be used to obtain informa-
tion on social demographics, background dairy consump-
tion and to identify barriers to lifestyle intervention 
Figure 2 Flow chart of the study recruitment and scheduled visits. GDM, gestational diabetes mellitus; IADPSG, International 
Association of the Diabetes and Pregnancy Study Groups; OGTT, oral glucose tolerance test.
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during pregnancy in all participating women. The 
barriers questionnaire is specifically designed to address 
ethnic- specific social and cultural barriers to lifestyle 
intervention during the pregnancy in both populations 
and would be administered at the start and the end of the 
study. The DAIRY consumption questionnaire used in this 
study is a modification the Dutch Dairy Food Frequency 
Questionnaire (Wageningen University, Department 
Human Nutrition, 2005).63 The questions relate to 
consumption of various dairy products divided into six 
different groups: total dairy, cheese, milk, nonfermented 
milk products, fermented milk and other dairy products. 
Flavoured milk, puddings and cream are all part of the 
non- fermented milk product group. The fermented milk 
products consist of yoghurt, yoghurt drinks and butter 
milk. Additional modifications to include other dairy 
preparations that are locally consumed in both countries 
are included.
Ultrasound scans
Ultrasound scans will be performed by an ultrasound- 
trained obstetrician on Voluson GE S-8 (in India) and 
Aloka USI-145 (in Gambia) ultrasound machines on all 
participates at three visits, (1) at screening (dating) (2) 
morphology scan at visit 1 (18–20 weeks GA) and (3) at 
visit 3 (week 32) for growth monitoring. Both centres 
will follow standard protocols as described in study SOPs. 
Evidence of fetal congenital anomaly, placental malfor-
mation or malposition or abnormal ultrasound features 
that can compromise pregnancy outcome will lead to 
termination of the participant’s involvement in the study 




Incidence of GDM diagnosed using IADPSG criteria 
between 26 and 28 weeks of gestation or if the fasting 
plasma glucose concentration is ≥5.1 mmol/L at 32 weeks 
of gestation.
Secondary outcomes
Effect of the intervention on fasting blood glucose concen-
tration at 32 weeks, GWG and BP from randomisation to 
week 32, proportion of women undergoing instrumental/










Week ≤18 Week 18–20 Week 26–28 Week 32
Informed consent X             
Eligibility assessment X             
Demographics X             
History X             
Height X             
Weight X X X X X X X
Blood pressure X X X X X X X
Antenatal examination X X X X X X   
Dairy consumption 
questionnaire
  X X X X X   
Barriers questionnaire X         X   
Baseline PA monitoring 
with Vivofit 4
  X           
PA step- count 
monitoring
    X X X X   
Randomisation     X         
OGTT X       X     
Dating scan X             
Morphology scan       X       
Ultrasound scan 
(growth)
          X   
Fasting plasma glucose           X   
Intrapartum 
assessment (mother)
            X
New born assessment             X
OGTT, oral glucose tolerance test; PA, physical activity.
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caesarean delivery, proportion of women developing 
pre- eclampsia and eclampsia, blood loss during delivery 
(subjective assessment by the obstetrician), postpartum 
haemorrhage, preterm births (<37 weeks GA), fetal 
macrosomia defined as birth weight >2 SDs above the 
population- specific mean in each setting, birth weight 
and length, APGAR score at 1 and 5 min and responses 
to questionnaire based assessments of barriers to lifestyle 
interventions in pregnancy.
ADVERSE/SERIOUS AES AND REPORTING
All adverse event (AE) and serious AEs (SAEs) will be 
captured in respective electronic Case Report Forms 
(eCRFs). Details of all events including onset date, rela-
tionship to the study intervention, treatment given and 
stop date will be captured in the respective AE report 
form. The PI will report all SAEs without filtration, 
whether or not related to the intervention, within 24 
hours of becoming aware of the event, to the sponsor. All 
SAEs will be notified to the respective Ethics Committee 
within seven calendar days if fatal or life- threatening, 
and all others within 15 calendar days. All AEs and SAEs 
will also be notified to the Data Safety and Monitoring 
Committee (DSMC). Expected SAEs which are protocol- 
defined exceptions to SAE reporting will be captured 
and reported to respective ethics committees (ECs) and 
DSMC as outlined in the protocol (online supplemental 
file 1).
STATISTICAL ANALYSIS PLAN INCLUDING SAMPLE SIZE AND 
POWER CALCULATION
Sample size
The sample size calculation was performed by simulation 
(in R V.3.5.2) using an algorithm as described in detail 
in the protocol (online supplemental file 1). After 10 000 
repetitions, we estimated the sample size to be 1856 high- 
risk women (928 from each centre). The sample size is 
estimated to have 80% power to detect a 33% reduction 
in the incidence of GDM, for the main effects of diet and 
PA, with a family- wise significance level of 5% for a two- 
sided test (ie, each effect was tested at a significance level 
of 2.5%). It was assumed that participants could be pooled 
across centres (no interaction between interventions and 
country at the 5% level). The sample size was inflated to 
allow for a 15% drop- out rate in each of the four strata, 
with drop outs defined as non- compliant participants (ie, 
no risk reduction in their incidence of GDM).
Data analysis
Data will be analysed using both (1) the intention- to- treat 
principle, including all enrolled participants regardless of 
their adherence to the proposed intervention and (2) a 
per protocol approach, including only those participants 
adhering to at least 75% of the proposed intervention. 
In addition, we will run a sensitivity analysis to assess 
the effect of protocol deviation compared with 100% 
adherence.
Descriptive analyses at baseline
We will describe baseline characteristics of the four 
groups (Control, yoghurt, PA, and yoghurt +PA) using 
means and standard deviations (normally distributed 
quantitative variables), medians and interquartile ranges 
(non- normally distributed quantitative variables) or 
proportions (categorical variables).
Primary analysis
For our primary outcome (presence or absence of GDM), 
we will use multiple logistic regression models and results 
presented as OR and 95% CI. We will examine the assump-
tion that there are no interaction effects between study 
centre and each of the interventions by fitting a multiple 
logistic regression model.
We will build two covariate adjusted models. First, we 
will assess the relative difference between centres in the 
effects of each intervention on GDM by adding a term for 
study centre. Second, we will fit a covariate (age, prepreg-
nancy BMI, previous history of GDM and GA) adjusted 
model adding further terms for each, as well as relevant 
interaction terms, to remove bias from the estimate of the 
treatment effect on the primary outcome. Each covariate 
will be added to the unadjusted model separately first and 
then added one at a time and kept in the model if their 
significance level is <10%.
Secondary analyses
Continuous variables will be analysed using multiple 
linear regression and binary variables by multiple logistic 
regression. For each secondary outcome, we will fit a 
simple model with only terms for each intervention, and a 
covariate adjusted model including terms for study centre 
and the remaining pre- specified covariates and relevant 
interactions.
DATA COLLECTION
Research data will be collected using eCRFs on tablets 
by designated study staff after training. Where there is 
internet connectivity, collected data will be stored directly 
onto the central server housed at MRC, Fajara and where 
there is no/unreliable connectivity, data will be stored 
locally on the tablet and later synchronised to the central 
servers. The accelerometer data used for PA monitoring 
will be directly synced with the Garmin app on the tablets 
on a weekly basis and transferred to eCRFs. To ensure 
standardisation of processes, SOPs with respect to trial 
management, quality assurance, data management, infor-
mation technology (IT) and security and statistics will be 
adhered to.
COMMITTEE OVERSIGHTS
The study will be conducted in accordance with the 
approved protocol, Good Clinical Practice regulations 
8 Vasan SK, et al. BMJ Open 2021;11:e042069. doi:10.1136/bmjopen-2020-042069
Open access 
and SOPs. The implementation of the study will be over-
seen by the trial steering committee (TSC). An inde-
pendent DSMC, composed of experts in clinical trials/
epidemiology, biostatistics and obstetrics will meet 
6- monthly to review the progress of the trial (recruit-
ment, compliance, lost to follow- up), clinical study safety 
data, data quality and assess and/or adjudicate all events 
of deaths, the GDM event rate and key secondary/safety 
outcomes and provide feedback to the TSC. The DSMC 
will also meet if required, more frequently depending 
on the enrolment rate, safety issues and AEs. A copy of 
the full study protocol and all amendments would be 
submitted to DSMC prior to study initiation and subse-
quently. Thereafter, periodic reports including summary 
of enrolment, demographics, protocol compliance and 
safety will be compiled by the study statistician and 
submitted at least 1 week prior to the scheduled meeting. 
The board will advise on continuation or stopping the 
trial based on safety and efficacy.
ETHICS AND DISSEMINATION
Ethical issues
The proposed interventions are considered generally 
safe both for maternal and fetal health. Participation in 
this trial is voluntary and subject to informed consent. 
A sample informed consent statement is available in the 
study protocol (online supplemental file 1). Participants 
who develop GDM at the visit 2 OGTT will be started 
on pharmacological therapy (as per local management 
guidelines) and results will be analysed as per intention to 
treat. Research participants can withdraw from the study 
at any time during the trial. The Standard Protocol Items: 
Recommendations for Interventional Trials Checklist for 
the protocol is detailed in online supplemental file 2.
Dissemination
Results of the study will be presented at major national 
and international conferences, and publish in peer- 
reviewed journals, ensuring open access and the highest 
possible impact. The deidentified data will be openly 
available to the scientific community after publication 
of initial results. We will interact with national and inter-
national health agencies and governments to stimulate 
translation of our findings into policy and expect our 
research to influence policy for mothers and children 
within the next 5–10 years.
Patient and public involvement
The trial was informed by patients’ need for effective 
preventive therapies for GDM since randomised trial 
data are lacking in these populations. Patients were not 
involved in the design, conduct or reporting of the study. 
A summary of the main trial results will be disseminated 
to the general public and study participants after the 
completion of the study.
DISCUSSION
GDM poses increased risks to maternal and child health. 
LMICs face numerous challenges to GDM care at various 
levels. These include (1) late second trimester screening 
for GDM, (2) lack of standardised nationwide guidelines 
for diagnosis, (3) interventions targeting only women 
who are diagnosed with GDM around 24–28 weeks, (4) 
lack of knowledge and awareness of GDM and its health 
implications and (5) sociocultural barriers to early ante-
natal care and life- style interventions during pregnancy. 
It seems very likely that early screening and establishment 
of positive lifestyle changes beginning from conception, 
or even prior to conception, particularly in selected high- 
risk women and especially in low- resource settings, will 
reduce the burden of GDM as well as improve both imme-
diate obstetric outcomes and long- term health of the 
mother and the new born. Primary prevention of GDM, 
rather than treatment initiated after GDM onset is likely 
to lead to both economic and individual health benefits.
The PRIMORDIAL study is timely given the increasing 
prevalence of both diabetes and obesity in countries like 
Africa and India. Our study provides a unique opportunity 
to test simple life- style interventions during pregnancy in 
the LMIC settings, which have never been undertaken. 
The results will add to the existing evidence of beneficial 
effects of yoghurt on several pregnancy- related outcomes.
The study is expected to bridge a gap in knowledge 
of the potential effectiveness of GDM prevention in 
two LMIC settings and create opportunities for capacity 
building in both India and The Gambia. We believe the 
trial can provide information that will aid in policy guide-
lines relating to GDM screening and management and 
also suggest areas that may require further research.
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